

**CNS Pharmaceuticals, Inc.**  
**2100 West Loop South, Suite 900**  
**Houston, TX 77027**

December 21, 2023

**VIA EDGAR**

United States Securities and Exchange Commission  
Division of Corporation Finance  
Office of Life Sciences  
100 F Street, N.E.  
Washington, D.C. 20549

**Re: CNS Pharmaceuticals, Inc.**  
**Registration Statement on Form S-1 (the "Registration Statement")**  
**File No. 333-275973**

Ladies and Gentlemen:

Reference is made to our letter, filed as correspondence with the U.S. Securities and Exchange Commission via EDGAR on December 20, 2023 regarding the acceleration of the effectiveness of the above-referenced Registration Statement to 5:00 P.M. (Eastern Time) on December 21, 2023. We hereby formally withdraw our prior request for acceleration of the effective date of such Registration Statement.

Very truly yours,  
**CNS Pharmaceuticals, Inc.**

By: /s/ Christopher Downs  
Name: Christopher Downs  
Title: Chief Financial Officer

cc: Cavas Pavri, ArentFox Schiff LLP